TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01288196
Drug: CNTO 6785 10 mg/kg IV
Approvals — FDA: no, EMA: no, PMDA: no
Description: A single 30-minute IV infusion of CNTO 6785 10 mg/kg
Study: NCT01288196
Drug: Placebo SC
Approvals — FDA: no, EMA: no, PMDA: no
Description: A single SC dose of placebo administered in up to 3 SC injections
Study: NCT01019694
Drug: Combivent CFC-MDI
Approvals — FDA: no, EMA: no, PMDA: no
Description: 36/206 mcg Four times a day (QID)
Study: NCT01019694
Drug: Combivent Respimat 20/100 mcg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Open label randomized parallel
Study: NCT03789760
Drug: SaiLuoTong capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 subjects are randomly divided into two groups by 3:1. 375 subjects in the active group take two pills(120mg) of SaiLuoTong capsule each time, twice a day, 0.5 hours before breakfast and dinner, taking with lukewarm water.
Study: NCT01543035
Drug: stop statin and switch to an antiretroviral drug with less impact on lipid metabolism
Approvals — FDA: no, EMA: no, PMDA: no
Description: Switch from a boosted PI or efavirenz based ART regimen to etravirine 400 mg/day once daily for patients in need of lipid lowering drugs (statin) after one month wash out of statin
Study: NCT00510536
Drug: Acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: dose to be determined by investigator
Study: NCT03061136
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02815332
Drug: BPX-01 1% Minocycline Topical Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Approximately 1 gram applied once daily for 12 weeks
Study: NCT02815332
Drug: BPX-01 2% Minocycline Topical Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Approximately 1 gram applied once daily for 12 weeks
Study: NCT02618616
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02682693
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide 600 mg/m² every 2 or 3 weeks for 4 times
Study: NCT00984893
Drug: zoledronic acid
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT00984893
Drug: Any oral bisphosphonates marketed in Canada
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00600912
Drug: SMOFlipid®
Approvals — FDA: no, EMA: no, PMDA: no
Description: continuously, for 5 days postoperatively, corresponding to the observation time. Nonprotein calories: to 60% as glucose and to 40% as lipid emulsion. The total energy intake per day was adjusted to 25 kcal kg-1 body weight.
Study: NCT03259464
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 sequential dose groups
Study: NCT01834742
Drug: NER1006
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single evening dose of 750mL solution containing 100g PEG3350 plus 6g sodium sulphate. Single morning dose containing 40g PEG3350, 33.9g sodium ascorbate, 20.1g ascorbic acid.
Study: NCT01834742
Drug: NER1006
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single evening dose of 750mL solution containing 100g PEG3350 plus 9g sodium sulphate. Single morning dose containing 40g PEG3350, 33.9g sodium ascorbate, 20.1g ascorbic acid.
Study: NCT01834742
Drug: NER1006
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single evening dose of 750mL solution containing 75g PEG3350 plus 5.6g sodium sulphate. Single morning dose containing 40g PEG3350, 33.9g sodium ascorbate, 20.1g ascorbic acid.
Study: NCT01834742
Drug: NER1006
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single evening dose containing formulation selected from Part A of study. Single morning dose containing 40g PEG3350 and 56.6g sodium ascorbate.
Study: NCT01834742
Drug: NER1006
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single evening dose containing formulation selected from Part A of study. Single morning dose containing 40g PEG3350, 33.9g sodium ascorbate and 21.4g magnesium ascorbate.
Study: NCT01834742
Drug: NER1006
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single evening dose containing formulation selected from Part A of study. Single morning dose containing 40g PEG3350, 6g sodium sulphate and 33.9g sodium ascorbate.
Study: NCT01834742
Drug: NER1006
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single evening dose containing formulation selected from Part A of study. Single morning dose containing 29g PEG3350 and 4.8g sulphate and 23.3g ascorbic acid.
Study: NCT00066482
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV over 1 hour. Children ≥ 12 months: Level 1: 1.2 g/m2/dose Level 2: 1.8 g/m2/dose Level 3: 2.4 g/m2/dose Children \< 12 months: Level 1: 40 mg/kg/dose Level 2: 60 mg/kg/dose Level 3: 80 mg/kg/dose Day 1 (Week 1, 4, 7, 10)
Study: NCT00410332
Drug: Traumeel S
Normalized name: Traumeel S Injection Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: homeopathic remedy
Study: NCT00410332
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo drug, identical in size, form and taste as treatment remedy
Study: NCT01602367
Drug: Placebo matching with BMS-823778
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsules, Oral, 0 mg, Once daily, 12 weeks
Study: NCT02244255
Drug: FLOMAX® capsules
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02244255
Drug: Ascending doses of HYTRIN® capsules
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02183038
Drug: Meloxicam low
Normalized name: Meloxicam
DrugBank: Meloxicam (DB00814)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02183038
Drug: Meloxicam high
Normalized name: Meloxicam
DrugBank: Meloxicam (DB00814)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02183038
Drug: Naproxen sodium
Normalized name: Naproxen Sodium
DrugBank: Naproxen (DB00788)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02183038
Drug: Meloxicam placebo low
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02183038
Drug: Meloxicam placebo high
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02183038
Drug: Naproxen sodium placebo
Normalized name: Naproxen Sodium
DrugBank: Naproxen (DB00788)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00638716
Drug: CJC-1134-PC
Normalized name: CJC-1295
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 or 2.0 mg CJC-1134-PC
Study: NCT00638716
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT02608216
Drug: [18F]FLT
Approvals — FDA: no, EMA: no, PMDA: no
Description: \[18F\]FLT PET/CT scan, imaging tracer
Study: NCT01073813
Drug: Minocycline
Normalized name: Minocycline
DrugBank: Minocycline (DB01017)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 100mg twice daily
Study: NCT02080780
Drug: Clarithromycin XL
Normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clarithromycin XL administered once daily on Days 4 through 9 as 2 x 500 mg tablets, 1000 mg per day, for a total of 6000 mg
Study: NCT00676364
Drug: Placebo cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: A dollop of matching placebo cream was applied under occlusive dressing for 15 mins prior to venipuncture
Study: NCT02782559
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Color and size matched to active drug (sildenafil)
Study: NCT00685399
Drug: AIN457
Approvals — FDA: no, EMA: no, PMDA: no
Description: AIN457 subcutaneous dose
Study: NCT00685399
Drug: AIN 457
Normalized name: Ainsliaea fragrans top extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: AIN457 low dose (i.v)
Study: NCT03028909
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salt-water solution containing no active ingredients.
Study: NCT00983060
Drug: NIM811
Approvals — FDA: no, EMA: no, PMDA: no
Description: BID in various doses (between 100 mg - 600 mg bid) + SOC (PEG IFN and RBV)
Study: NCT01311076
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAK-329 placebo-matching tablets, orally, single dose, one day.
Study: NCT02215395
Drug: NES/EE CVR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent administration of vaginal antimycotic medication (Miconazole Nitrate) on the pharmacokinetics of Nestorone (NES) and ethinyl estradiol (EE) delivered by a contraceptive vaginal ring (CVR)
Study: NCT01863199
Drug: Lucentis every 12 weeks
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lucentis 0.5mg administered intravitreally every twelve weeks for 12 months
Study: NCT02218047
Drug: Pegylated-Proline-interferon alpha-2b
Normalized name: Pegylated proline interferon alpha-2b
DrugBank: Ropeginterferon alfa-2b (DB15119)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Subjects will continue to receive the dosage which delivers the optimal disease response (hematocrit \[Hct\]\<45%, platelets \[PLTs\]\<400 x 109/L and leukocytes \[WBCs\]\<10 x 109/L), as determined in the PROUD-PV study, preferably at the level of target blood values.
Study: NCT02218047
Drug: Best available therapy (BAT)
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Best available therapy as selected by the investigator
Study: NCT00627965
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tds
Study: NCT02166398
Drug: UI15AML055MT
Approvals — FDA: no, EMA: no, PMDA: no
Description: tab, PO
Study: NCT02166398
Drug: Amosartan 5/50
Approvals — FDA: no, EMA: no, PMDA: no
Description: tab, PO
Study: NCT03001635
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: 26 patients will receive 0.9% normal saline infusion for 6h as placebo
Study: NCT05037045
Drug: GLP-1 receptor agonist
Normalized name: GLP-1 receptor agonist
Approvals — FDA: no, EMA: no, PMDA: no
Description: GLP-1 RA was injected subcutaneously at standard dose and frequency for consecutive 6 months in patients with T2DM
Study: NCT02589626
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: For blinding purposes
Study: NCT00762268
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02546310
Drug: HTL0009936
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02546310
Drug: HTL0009936 matching placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00044629
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01533324
Drug: S-1 combined with Leucovorin
Normalized name: (S)-Leucovorin
DrugBank: (6R)-Folinic acid (DB03256)
Approvals — FDA: no, EMA: no, PMDA: no
Description: S-1 capsules 80mg/m2/d BID one week on and one week off Leucovorin tablets 50mg/d BID one week on and one week off
Study: NCT02216942
Drug: Endodontic treatment using Vitapex
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endodontic treatment using Vitapex
Study: NCT02216942
Drug: Endodontic treatment using Guedes Pinto
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endodontic treatment using Guedes Pinto paste
Study: NCT02423395
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: calcium in muscle cramps in cirrhotic patients
Study: NCT00542880
Drug: Symbicort Turbuhaler (budesonide/formoterol) 320/9 μg
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00542880
Drug: Seretide Diskus (salmeterol/fluticasone) 50/500 μg
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00647465
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT02842580
Drug: 5 FLUOROURACYL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Folinic acid is administered IV at a dose of 400 mg/m² (or 200 mg/m² if Elvorine) as a 2 hr infusion.~The 5FU bolus is administered in less than 10 minutes at 400 mg/m² (on D1). The continuous 5FU is administered IV at a dose of 2400 mg/m² over 46 hr (D1 and D2).~The cycles will last 14 days. For this 1st line chemotherapy, the investigator has the choice of using capecitabine instead of LV5FU2; in this case the cycle lasts 21 days.
Study: NCT01323530
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral film-coated tablets.
Study: NCT00245089
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01102257
Drug: Omega-3 EFA Supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: The total daily dose from the 5 capsules in treatment group will be 3.0 grams of omega-3 EFAs comprised of:~2000 mg EPA 1000 mg DHA
Study: NCT02492984
Drug: Intravenous infusions of Xyntha
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enrolled subjects will be treated with intravenous infusions of Xyntha for: • On-Demand treatment, • Surgical Prophylaxis at a dose and frequency prescribed by the subject's treating physician in accordance with the Xyntha label and will be adjusted solely according to medical and therapeutic necessity.
Study: NCT00003446
Drug: fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00003446
Drug: leucovorin calcium
Normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00911469
Drug: AS902330
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3, 10, 30, 100 or 300 µg intra-articular injection per subject in the Single Ascending Dose (SAD) cohorts and 10, 30, 100, 300 µg or highest tolerated dose intra-articular injection per week for three weeks per subject in the Multiple Ascending Dose (MAD) cohorts.
Study: NCT00911469
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo or, 3, 10, 30, 100 or 300 µg intra-articular injection per subject in SAD cohorts and placebo or, 10, 30, 100, 300 µg or highest tolerated dose of AS902330 intra-articular injection per week for three weeks per subject in MAD cohorts.
Study: NCT01676935
Drug: ABT-126
Normalized name: ABT-925
Approvals — FDA: no, EMA: no, PMDA: no
Description: See arm description
Study: NCT00140244
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01609855
Drug: Hyoscine Butyl Bromide 20mg/2 ml i.v.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyoscine Butyl Bromide 20mg/2 ml i.v.is administered at time of caecal intubation
Study: NCT01609855
Drug: Saline 2 ml i.v.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration of Saline 2 ml at time of caecal intubation
Study: NCT00424619
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, 1 time bolus dose
Study: NCT02467790
Drug: PEX168
Approvals — FDA: no, EMA: no, PMDA: no
Description: PEX 168: 200µg,Subcutaneous,one time.
Study: NCT00083759
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00921557
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral tablet taken once weekly
Study: NCT00656292
Drug: Simvastatin
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 40 mg po/nasogastric tube (NG) every day for 6 days
Study: NCT00656292
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 pill po/NG every day x 6 days
Study: NCT04441528
Drug: Baby shampoo
Normalized name: BABY SHAMPOO
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baby will be used in 24 patients for 8 weeks and will be discontinued in the following 4 weeks.
Study: NCT02564900
Drug: DS-8201a (DP1)
Normalized name: Uretron DS
Approvals — FDA: no, EMA: no, PMDA: no
Description: DS-8201a to be administered via intravenous (IV) dose. DS-8201a (DP1) was used for the Dose Escalation phase and for Dose expansion Parts 2a, 2b, 2c, and 2d.
Study: NCT02564900
Drug: DS-8201a (DP)
Normalized name: Uretron DS
Approvals — FDA: no, EMA: no, PMDA: no
Description: DS-8201a (DP) is to be administered via intravenous (IV) dose.
Study: NCT00281788
Drug: capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00109031
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide is administered at a total dose of 100 mg/kg given in 1 dose on Day -2
Study: NCT00463047
Drug: Fentanyl Buccal Tablets Compared With Immediate-Release Oxycodone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will be randomly assigned in a 1:1 ratio either to titrate immediate-release oxycodone first and to titrate FBT second, or to titrate FBT first and immediate-release oxycodone second, followed by 2 double-blind crossover treatment periods (in randomized order). For the double-blind treatment period of the study involving FBT administration, a patient is randomly assigned to receive FBT at the 200, 400, 600, or 800 mcg strength found to be successful during open-label titration. For the double-blind treatment period of the study to which a patient is randomly assigned to receive immediate-release oxycodone, the patient will receive immediate-release oxycodone at the strength (15, 30, 45, or 60 mg) found to be successful during open-label titration.
Study: NCT02807727
Drug: Modified Ringers Lactate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single intravenous bolus dose of 1.5 ml/kg over 3 minutes
Study: NCT02384746
Drug: MLN9708
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will be treated in 3 dose cohorts of MLN9708, at 2.3, 3, and 4 mg orally on days 1, 4, 8, and 11 every 21 days.
Study: NCT00109031
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered as one daily intravenous bolus.
Study: NCT01834885
Drug: QVA149
Approvals — FDA: no, EMA: no, PMDA: no
Description: QVA149 via inhaler twice a day
Study: NCT01585740
Drug: 0.9% Normal Saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Crystalloid fluid
Study: NCT01585740
Drug: Ringer's Lactate
Normalized name: Ringer's lactate/gel dressing 2.2" TOPICAL KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Crystalloid fluid
Study: NCT02729766
Drug: Placebo P-Tablet
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00000412
Drug: Placebo Alendronate
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01985841
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Endoxan
Study: NCT03076970
Drug: matching placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: single oral tablet -given with single lasmiditan tablet and with single sumatriptan tablet.
Study: NCT02219893
Drug: MOC31PE Immunotoxin
Normalized name: hepatitis B immunoglobin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients who meet inclusion criteria will be treated with a single intraperitoneal MOC31PE immunotoxin instillation for 6 hours on the first day after CRS and HIPEC
Study: NCT04421287
Drug: Zhenyuan capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.25g/ tablets, 2 tablets / TID, for 12 weeks
Study: NCT01263236
Drug: LY2940094
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally
Study: NCT01263236
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally
Study: NCT02910206
Drug: Sufentanil
Normalized name: Sufentanil
DrugBank: Sufentanil (DB00708)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: sufentanil is given intravenously
Study: NCT02425878
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00619892
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive daily dosing at night with caplets matching the appearance of the active drug. However, caplets will not contain any active medication.
Study: NCT00593567
Drug: gentamicin-collagen sponge
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inserted daily into open ulcer
Study: NCT02901067
Drug: Aspirin and Rosuvastatin
Normalized name: rosuvastatin and ezetimibe
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Patients assigned to the intervention arm will receive the standard of care anti-coagulation plus the combination experimental drugs (20mg of rosuvastatin daily and 325mg of aspirin) daily either orally or via feeding tube.
Study: NCT01289639
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo 1 capsule po qd
Study: NCT00081224
Drug: capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00081224
Drug: celecoxib
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02780713
Drug: AZD9496 (Reference)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD9496 (Reference)
Study: NCT02780713
Drug: AZD9496 Variant A
Normalized name: Valiant Barrier
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD9496 Variant A.
Study: NCT02114229
Drug: methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Methotrexate will be given at a dose of 5 g/m\^2/dose as an intravenous infusion over 24 hours on day 1 of each induction cycle except in patients ≤ 31 days of age at enrollment. These young infants will receive methotrexate at a reduced dose of 2.5g/m\^2/dose.
Study: NCT00844857
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orally, once daily in the evening for 8 weeks.
Study: NCT02114229
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide will be given 1.5 g/m\^2 IV infusion during induction and consolidation.
Study: NCT01910480
Drug: NBI-98854 50 mg capsule once daily
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02436694
Drug: Local Anesthetic ropivacaíne
Approvals — FDA: no, EMA: no, PMDA: no
Description: Femoral and sciatic nerve block with ropivacaíne
Study: NCT00842920
Drug: Simvastatin 60 mg
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 60 mg once daily
Study: NCT00842920
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: one tablet once daily
Study: NCT00842920
Drug: Simvastatin 20 mg
Normalized name: simvastatin 20 MG
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 20 mg once daily
Study: NCT01875757
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02285166
Drug: Standard antihyperlipidemic therapy other than administration of omega-3 fatty acid ethyl esters (Lotriga).
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01661101
Drug: Placebo (for Dabigatran)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dabigatran placebo taken twice daily
Study: NCT01661101
Drug: Placebo (for Omeprazole)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole placebo taken once daily
Study: NCT02571101
Drug: CDFR0812-15/50mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Contains chlomipramine HCl 15mg and sildenafil citrate 50mg.
Study: NCT01615874
Drug: BDP hydrofluoroalkane (HFA) 80 mcg
Normalized name: HYDROFLUOROALKANE
Approvals — FDA: no, EMA: no, PMDA: no
Description: BDP HFA 80 mcg, 2 inhalations BID